Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis, 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016" report to their offering.

Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2016 provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages.

Breast cancer is the condition where the cells of the breast area become tumorous, that is, they undergo unlimited cell division. Both women and men are affected but chances of men being diagnosed with breast cancer are rare. Each year about 2,300 new cases of breast cancer in men and about 230,000 new cases in women are diagnosed. It is the second most common cancer among women in USA.

This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years.

Key Topics Covered:

  1. Introduction
  2. Disease Introduction
  3. Types Of Breast Cancer
  4. Staging of Breast Cancer
  5. Pathophysiology
  6. Etiology
  7. Risk Factors
  8. Diagnosis
  9. Pathology
  10. Survival Rates
  11. Treatment Landscape
  12. Treatment Algorithm
  13. Treatment By Stages
  14. Current medications in Practice
  15. Treatment for Premenopausal Women
  16. Treatment for Postmenopausal Women
  17. Treatment Follow-Up
  18. Market Drivers
  19. Market Barriers
  20. Marketed Products Analysis
  21. Market Analysis By Type Of Therapy
  22. Market Analysis By Launch Date, Annual Sales and Patent Expiry

Marketed Products Profile

- Hormone Therapy

- Aromasin (Exmestane)

- Evista

- Ibrance

- Femara

- Fareston

- Chemotherapy

- Halaven

- Taxotere

Companies Mentioned

- Sanofi-Aventis

- Astellas Pharma

- Pfizer Inc.

- Novartis Pharmaceuticals

- Astrazeneca, Inc.

For more information visit http://www.researchandmarkets.com/research/hd9dd5/estrogen_receptor

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health